ClinicalTrials.gg
CompletedNCT00909857Updated Aug 24, 2015Results posted

Effect on Primary Dysmenorrhea

A Phase 3 interventional study of Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027) and Ethinyl estradiol, Levonorgestrel (Miranova) in Primary Dysmenorrhea, sponsored by Bayer. Completed at 42 sites in 6 countries. Open to female participants aged 14 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-08-24.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
507
Allocation
Randomized
Ages
14 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Dysmenorrhea by Bayer — none open to participants now, none under way, none of them phase 3. Dysmenorrhea · Bayer.

Started
2009
the only one that year
Phase 3
4 of 11
none open now
Registered
4th of 11
by date

Among the 11 studies in Dysmenorrhea by Bayer, this one is the only one that started in 2009, is one of 4 in phase 3, and was the 4th registered.

Dysmenorrhea

432 studies on the registry are indexed under Dysmenorrhea; 109 are open to participants now.

Browse Dysmenorrhea studies →

Open to participants now

None of the 11 studies in Dysmenorrhea by Bayer is open now. The open studies under Dysmenorrhea, anywhere →

Who these studies take

Of the 59 Dysmenorrhea studies recruiting now, 7 (12%) set no upper age limit and 51 (86%) stop at 75 or younger; 11 take children under 18; 20 take healthy volunteers.

This study: 14 Years to 50 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Dysmenorrhea by Bayer as a file.
02

Study summary

To investigate the potential benefits of a new oral contraceptive (SH T00658ID) on alleviating complaints of dysmenorrhea associated with oral contraceptive use.

03

Conditions studied

  • Primary Dysmenorrhea

Browse trials for

Keywords

  • Primary Dysmenorrhea
  • Oral Contraception
04

Who can participate

Ages eligible
14 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Otherwise healthy female subjects requesting and suffering from primary dysmenorrhea with a sum score for dysmenorrheic pain intensity of >/= 8 over 2 baseline cycles documented by a prospective self-rated sum pain score
  • Age: 14 - 50 years (inclusive; smokers must not be older than 30 years) at the time point of
  • Normal cervical smear not requiring further follow-up (a cervical smear has to be taken at the screening visit, or a normal result has to be available that was documented within the last 6 months before the screening visit)
  • Women with cyclic menstrual bleeding, defined by a cycle length between 25 and 35 days and no amenorrheic cycles or cycles without withdrawal bleeding during the last 3 months prior to visit 1.
  • Able to tolerate ibuprofen and willing to use only Ibuprofen supplied for the study.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or lactation (delivery, abortion, or lactation within three cycles before the start of treatment)
  • Obesity: (BMI) > 32 kg/m2
  • to any of the study drug ingredients
  • Any diseases or conditions that might interfere with the conduct of the study or the interpretation of the results
  • Presence or a history of venous or arterial thrombotic / thromboembolic events (e.g. deep venous thrombosis, pulmonary embolism, myocardial infarction) or of a cerebrovascular accident, including prodromi (e.g. , angina pectoris), and conditions that could increase the risk of suffering from any of the above mentioned disorders, e.g. a family history indicating a hereditary predispositionUndiagnosed abnormal genital bleeding
  • Abuse of alcohol, drugs, or medicines (e.g. laxatives)
  • Other methods:

    • Sterilization
    • Oral, vaginal or transdermal hormonal contraception during treatment
    • Intra-uterine devices (IUD) with or without hormone release still in place within 30 days of visit 1
  • Simultaneous participation in another clinical trial or participation in another clinical trial prior to study entry that might have an impact on the study objectives at the discretion of the investigator
  • Major surgery scheduled for the study period
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
507 participants (actual)

Study arms

  • Experimental
    Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)

    Daily oral administration of one tablet SH T00658ID (BAY86-5027) plus one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles

    Drug: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027) · Drug: Placebo Match to SH T00658ID

  • Active comparator
    Ethinyl estradiol, Levonorgestrel (Miranova)

    Daily oral administration of one tablet placebo plus one tablet SH D593B (Miranova) for 28 days without tablet-free interval for 3 treatment cycles

    Drug: Ethinyl estradiol, Levonorgestrel (Miranova) · Drug: Placebo Match to SH D593B

Interventions

  • DrugEstradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)

    Drug pages: Estradiol · Dienogest

    Daily oral administration of one tablet SH T00658ID for 28 days per cycle in the respective treatment period; no tablet-free interval

  • DrugEthinyl estradiol, Levonorgestrel (Miranova)

    Drug pages: Ethinyl Estradiol · Levonorgestrel

    Daily oral administration of one tablet for 28 days per cycle in the respective treatment period; no tablet-free interval

  • DrugPlacebo Match to SH T00658ID

    Daily oral administration of one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles.

  • DrugPlacebo Match to SH D593B

    Daily oral administration of one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles.

06

What researchers measure

Primary outcomes

  1. Change Between Baseline Evaluation Period and Treatment Evaluation Period in the Number of Days With Dysmenorrheic Pain

    Dysmenorrheic pain was defined as pelvic pain during the menstrual/withdrawal bleeding episode and the 2 days before this episode. Baseline period: 2 days before the first menstrual bleeding until 3rd day before the 3rd menstrual bleeding (normalized to a standard 56-day period). Treatment period: 2 days before the withdrawal bleeding (WB) of the 1st evaluable treatment cycle until 3rd day before the WB of the cycle after the 2nd evaluable treatment cycle (normalized to a standard 56-day period).

    Time frame: baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)

Secondary outcomes

  1. Change Between Baseline Evaluation Period and Treatment Evaluation Period in the Sum of Score Points of Dysmenorrheic Pain

    Dysmenorrheic pain: pelvic pain during menstrual/withdrawal bleeding (WB) episode and 2 days before. Scores per day: 0 No pain; 1 Mild pain with no need for painkiller; 2 Moderate pain with need for painkiller; 3 Severe pain with need for painkiller. Baseline period: 2 days before 1st menstrual bleeding until 3rd day before 3rd menstrual bleeding (normalized to standard 56-day period). Treatment period: 2 days before WB of 1st treatment cycle until 3rd day before WB of the cycle after 2nd treatment cycle (normalized to standard 56-day period). Score difference min -168 (best), max 168 (worst)

    Time frame: baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)

  2. Change Between Baseline Evaluation Period and Treatment Evaluation Period in Number of Days With Pelvic Pain Independent of Occurrence of Vaginal Bleeding

    Baseline period: 2 days before the first menstrual bleeding until 3rd day before the 3rd menstrual bleeding (normalized to a standard 56-day period). Treatment period: 2 days before the withdrawal bleeding (WB) of the 1st evaluable treatment cycle until 3rd day before the WB of the cycle after the 2nd evaluable treatment cycle (normalized to a standard 56-day period).

    Time frame: baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)

  3. Change Between Baseline Evaluation Period and Treatment Evaluation Period in Number of Days With Pelvic Pain During Unscheduled Bleeding

    Evaluated was the number of days with bleeding-associated pelvic pain, excluding days during withdrawal bleeding (WB) and the 2 days preceding such WB, and during administration deviation bleeding and the 2 days preceding such bleeding (normalized to a standard 56-day period). Baseline period: 2 days before first menstrual bleeding until 3rd day before 3rd menstrual bleeding (normalized to standard 56-day period). Treatment period: 2 days before WB of the 1st treatment cycle until 3rd day before the WB of the cycle after the 2nd treatment cycle (normalized to standard 56-day period).

    Time frame: baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)

  4. Change Between Baseline Evaluation Period and Treatment Evaluation Period in Rescue Medication Use (Only Bleeding Episodes Used Including the Two Days Before the Episode)

    Rescue medication use was standardized intake of 200 mg Ibuprofen tablets. Baseline period: 2 days before the first menstrual bleeding until 3rd day before the 3rd menstrual bleeding (normalized to a standard 56-day period). Treatment period: 2 days before the withdrawal bleeding (WB) of the 1st evaluable treatment cycle until 3rd day before the WB of the cycle after the 2nd evaluable treatment cycle (normalized to a standard 56-day period).

    Time frame: baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)

  5. Change Between Baseline Evaluation Period and Treatment Evaluation Period in Rescue Medication Use (Entire Evaluation Period Used)

    Rescue medication use was standardized intake of 200 mg Ibuprofen tablets. Baseline period: 2 days before the first menstrual bleeding until 3rd day before the 3rd menstrual bleeding (normalized to a standard 56-day period). Treatment period: 2 days before the withdrawal bleeding (WB) of the 1st evaluable treatment cycle until 3rd day before the WB of the cycle after the 2nd evaluable treatment cycle (normalized to a standard 56-day period).

    Time frame: baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)

  6. Percentage of Participants With Interference of Dysmenorrheic Pain With Work/School and Social or Other Activity (Only Bleeding Episodes Used Including the Two Days Before)

    Interference of dysmenorrheic pain with work/school and social or other activity was assessed (yes/no). Baseline period: 2 days before the first menstrual bleeding until 3rd day before the 3rd menstrual bleeding (normalized to a standard 56-day period). Treatment period: 2 days before the withdrawal bleeding (WB) of the 1st evaluable treatment cycle until 3rd day before the WB of the cycle after the 2nd evaluable treatment cycle (normalized to a standard 56-day period).

    Time frame: baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)

  7. Percentage of Participants With Interference of Dysmenorrheic Pain With Work/School and Social or Other Activity (Entire Evaluation Period Used)

    Interference of dysmenorrheic pain with work/school and social or other activity was assessed (yes/no). Baseline period: 2 days before the first menstrual bleeding until 3rd day before the 3rd menstrual bleeding (normalized to a standard 56-day period). Treatment period: 2 days before the withdrawal bleeding (WB) of the 1st evaluable treatment cycle until 3rd day before the WB of the cycle after the 2nd evaluable treatment cycle (normalized to a standard 56-day period).

    Time frame: baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)

  8. Percentage of Participants Satisfied With Study Treatment

    Participants were asked to express the degree of their satisfaction with study treatment.

    Time frame: From cycle 1 to cycle 3 (28 days per cycle)

  9. Number of Days With Bleeding or Spotting

    Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.

    Time frame: From day 1 to day 90

  10. Number of Episodes With Bleeding or Spotting

    Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.

    Time frame: From day 1 to day 90

  11. Mean Length of Bleeding or Spotting Episodes

    Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.

    Time frame: From day 1 to day 90

  12. Maximum Length of Bleeding or Spotting Episodes

    Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.

    Time frame: From day 1 to day 90

  13. Difference in Duration Between Longest and Shortest Bleeding or Spotting Episode

    Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.

    Time frame: From day 1 to day 90

  14. Number of Days With Spotting-only

    Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.

    Time frame: From day 1 to day 90

  15. Number of Episodes With Spotting-only

    Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.

    Time frame: From day 1 to day 90

  16. Mean Length of Spotting Only Episodes

    Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.

    Time frame: From day 1 to day 90

  17. Maximum Length of Spotting Only Episodes

    Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.

    Time frame: From day 1 to day 90

  18. Difference in Duration Between Longest and Shortest Spotting Only Episode

    Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.

    Time frame: From day 1 to day 90

  19. Percentage of Participants With Withdrawal Bleeding at Cycle 1

    Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.

    Time frame: At cycle 1 (28 days per cycle)

  20. Percentage of Participants With Withdrawal Bleeding at Cycle 3

    Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.

    Time frame: At cycle 3 (28 days per cycle)

  21. Length of Withdrawal Bleeding Episodes at Cycle 1

    Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.

    Time frame: At cycle 1 (28 days per cycle)

  22. Length of Withdrawal Bleeding Episodes at Cycle 3

    Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.

    Time frame: At cycle 3 (28 days per cycle)

  23. Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 1

    Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. Intensity was defined as: 1 = none, 2 = spotting, 3 = light, 4 = normal, 5 = heavy.

    Time frame: At cycle 1 (28 days per cycle)

  24. Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 3

    Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. Intensity was defined as: 1 = none, 2 = spotting, 3 = light, 4 = normal, 5 = heavy.

    Time frame: At cycle 3 (28 days per cycle)

  25. Onset of Withdrawal Bleeding Episodes at Cycle 1

    Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.

    Time frame: At cycle 1 (28 days per cycle)

  26. Onset of Withdrawal Bleeding Episodes at Cycle 3

    Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.

    Time frame: At cycle 3 (28 days per cycle)

  27. Percentage of Participants With Intracyclic Bleeding at Cycle 1

    Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.

    Time frame: At cycle 1 (28 days per cycle)

  28. Percentage of Participants With Intracyclic Bleeding at Cycle 3

    Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.

    Time frame: At cycle 3 (28 days per cycle)

  29. Number of Intracyclic Bleeding Episodes at Cycle 1

    Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.

    Time frame: At cycle 1 (28 days per cycle)

  30. Number of Intracyclic Bleeding Episodes at Cycle 3

    Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.

    Time frame: At cycle 3 (28 days per cycle)

  31. Maximum Length of Intracyclic Bleeding Episodes at Cycle 1

    Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.

    Time frame: At cycle 1 (28 days per cycle)

  32. Maximum Length of Intracyclic Bleeding Episodes at Cycle 3

    Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.

    Time frame: At cycle 3 (28 days per cycle)

  33. Number of Intracyclic Bleeding Days at Cycle 1

    Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. The total number of days during intracyclic bleeding episodes was counted.

    Time frame: At cycle 1 (28 days per cycle)

  34. Number of Intracyclic Bleeding Days at Cycle 3

    Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. The total number of days during intracyclic bleeding episodes was counted.

    Time frame: At cycle 3 (28 days per cycle)

  35. Percentage of Participants With Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 1

    Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. Intensity could be described as spotting, light, normal or heavy.

    Time frame: At cycle 1 (28 days per cycle)

  36. Percentage of Participants With Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 3

    Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. Intensity could be described as spotting, light, normal or heavy.

    Time frame: At cycle 3 (28 days per cycle)

  37. Percentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Screening

    The investigator was asked to interview the participant and record the number of missed hours/days from work due to dysmenorrheic pain in the previous menstrual cycle.

    Time frame: At screening (28 days)

  38. Percentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Baseline Cycle

    The investigator was asked to interview the participant and record the number of missed hours/days from work due to dysmenorrheic pain in the previous menstrual cycle.

    Time frame: At Baseline (28 days per cycle)

  39. Percentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Cycle 2

    The investigator was asked to interview the participant and record the number of missed hours/days from work due to dysmenorrheic pain in the previous menstrual cycle.

    Time frame: At cycle 2 (28 days per cycle)

  40. Percentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Final Examination

    The investigator was asked to interview the participant and record the number of missed hours/days from work due to dysmenorrheic pain in the previous menstrual cycle.

    Time frame: At final examination (28 days)

  41. Own Costs of Physiotherapy Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire

    The participants were asked to complete a resource use questionnaire indicating their own costs of physiotherapy per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars.

    Time frame: At screening (average over 3 months before screening)

  42. Own Costs of Pain Medication Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire

    The participants were asked to complete a resource use questionnaire indicating their own costs of pain medication per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars.

    Time frame: At screening (average over 3 months before screening)

  43. Own Costs of Vitamins Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire

    The participants were asked to complete a resource use questionnaire indicating their own costs of vitamins per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars.

    Time frame: At screening (average over 3 months before screening)

  44. Own Costs of Massages Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire

    The participants were asked to complete a resource use questionnaire indicating their own costs of massages per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars.

    Time frame: At screening (average over 3 months before screening)

  45. Own Costs of Acupuncture Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire

    The participants were asked to complete a resource use questionnaire indicating their own costs of acupuncture per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars.

    Time frame: At screening (average over 3 months before screening)

  46. Own Costs of Medical Counseling Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire

    The participants were asked to complete a resource use questionnaire indicating their own costs of medical counseling per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars.

    Time frame: At screening (average over 3 months before screening)

  47. Own Costs of Alternative Medicine Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire

    The participants were asked to complete a resource use questionnaire indicating their own costs of alternative medicine per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars.

    Time frame: At screening (average over 3 months before screening)

  48. Own Costs of Herbs/Teas Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire

    The participants were asked to complete a resource use questionnaire indicating their own costs of herbs/teas per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars.

    Time frame: At screening (average over 3 months before screening)

  49. Other Own Costs Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire

    The participants were asked to complete a resource use questionnaire indicating their other own costs per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars.

    Time frame: At screening (average over 3 months before screening)

  50. Participants With Improvement in the Investigators' Assessment in the Clinical Global Impression

    The Clinical Global Impression Scale (CGI) is a widely used rating scale/assessment instrument in psychopharmacology research in general, and in studies on women's health in particular. Investigators were asked to rate the participants' improvement during the course of the study.

    Time frame: At cycle 2 (28 days per cycle)

  51. Participants With Improvement in Participants' Assessment in the Clinical Global Impression

    The Clinical Global Impression Scale (CGI) is a widely used rating scale/assessment instrument in psychopharmacology research in general, and in studies on women's health in particular. Participants were asked to rate their improvement during the course of the study.

    Time frame: At cycle 2 (28 days per cycle)

  52. Physical Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle

    The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)

    Time frame: At baseline cycle (28 days per cycle)

  53. Physical Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination

    The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)

    Time frame: at final examination (28 days)

  54. Social Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle

    The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)

    Time frame: At baseline cycle (28 days per cycle)

  55. Social Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination

    The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)

    Time frame: At final examination (28 days)

  56. Mental Health as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle

    The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)

    Time frame: At baseline cycle (28 days per cycle)

  57. Mental Health as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination

    The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)

    Time frame: At final examination (28 days)

  58. Vitality as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle

    The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)

    Time frame: At baseline cycle (28 days per cycle)

  59. Vitality as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination

    The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)

    Time frame: At final examination (28 days)

  60. General Health as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle

    The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)

    Time frame: At baseline cycle (28 days per cycle)

  61. General Health as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination

    The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)

    Time frame: At final examination (28 days)

  62. Role Physical as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle

    The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)

    Time frame: At baseline cycle (28 days per cycle)

  63. Role Physical as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination

    The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)

    Time frame: At final examination (28 days)

  64. Role Emotional as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle

    The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)

    Time frame: At baseline cycle (28 days per cycle)

  65. Role Emotional as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination

    The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)

    Time frame: At final examination (28 days)

  66. Bodily Pain as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle

    The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)

    Time frame: At baseline cycle (28 days per cycle)

  67. Bodily Pain as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination

    The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)

    Time frame: At final examination (28 days)

07

Results

Posted Feb 27, 2012

Participant flow

Participants aged 14 to 50 years with a need for oral contraception suffering from primary dysmenorrhea were recruited at specialized study sites.

Participant flow — Overall Study
MilestoneEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Started253254
Treated234230
Completed217209
Not completed3645
Withdrew: Withdrawal by subject610
Withdrew: Adverse event55
Withdrew: Lost to follow-up25
Withdrew: Protocol violation21
Withdrew: Pregnancy10
Withdrew: Other10
Withdrew: Did not receive study medication1924

Outcome measures

PrimaryChange Between Baseline Evaluation Period and Treatment Evaluation Period in the Number of Days With Dysmenorrheic Pain

Dysmenorrheic pain was defined as pelvic pain during the menstrual/withdrawal bleeding episode and the 2 days before this episode. Baseline period: 2 days before the first menstrual bleeding until 3rd day before the 3rd menstrual bleeding (normalized to a standard 56-day period). Treatment period: 2 days before the withdrawal bleeding (WB) of the 1st evaluable treatment cycle until 3rd day before the WB of the cycle after the 2nd evaluable treatment cycle (normalized to a standard 56-day period).

Time frame:
baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)
Reported as:
Mean · Days
Change Between Baseline Evaluation Period and Treatment Evaluation Period in the Number of Days With Dysmenorrheic Pain
DaysEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Change Between Baseline Evaluation Period and Treatment Evaluation Period in the Number of Days With Dysmenorrheic Pain-4.6 ± 4.6-4.2 ± 4.2
SecondaryChange Between Baseline Evaluation Period and Treatment Evaluation Period in the Sum of Score Points of Dysmenorrheic Pain

Dysmenorrheic pain: pelvic pain during menstrual/withdrawal bleeding (WB) episode and 2 days before. Scores per day: 0 No pain; 1 Mild pain with no need for painkiller; 2 Moderate pain with need for painkiller; 3 Severe pain with need for painkiller. Baseline period: 2 days before 1st menstrual bleeding until 3rd day before 3rd menstrual bleeding (normalized to standard 56-day period). Treatment period: 2 days before WB of 1st treatment cycle until 3rd day before WB of the cycle after 2nd treatment cycle (normalized to standard 56-day period). Score difference min -168 (best), max 168 (worst)

Time frame:
baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)
Reported as:
Mean · Scores on a scale
Change Between Baseline Evaluation Period and Treatment Evaluation Period in the Sum of Score Points of Dysmenorrheic Pain
Scores on a scaleEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Change Between Baseline Evaluation Period and Treatment Evaluation Period in the Sum of Score Points of Dysmenorrheic Pain-10.6 ± 9.7-10.0 ± 8.9
SecondaryChange Between Baseline Evaluation Period and Treatment Evaluation Period in Number of Days With Pelvic Pain Independent of Occurrence of Vaginal Bleeding

Baseline period: 2 days before the first menstrual bleeding until 3rd day before the 3rd menstrual bleeding (normalized to a standard 56-day period). Treatment period: 2 days before the withdrawal bleeding (WB) of the 1st evaluable treatment cycle until 3rd day before the WB of the cycle after the 2nd evaluable treatment cycle (normalized to a standard 56-day period).

Time frame:
baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)
Reported as:
Mean · Days
Change Between Baseline Evaluation Period and Treatment Evaluation Period in Number of Days With Pelvic Pain Independent of Occurrence of Vaginal Bleeding
DaysEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Change Between Baseline Evaluation Period and Treatment Evaluation Period in Number of Days With Pelvic Pain Independent of Occurrence of Vaginal Bleeding-4.0 ± 5.7-3.7 ± 5.7
SecondaryChange Between Baseline Evaluation Period and Treatment Evaluation Period in Number of Days With Pelvic Pain During Unscheduled Bleeding

Evaluated was the number of days with bleeding-associated pelvic pain, excluding days during withdrawal bleeding (WB) and the 2 days preceding such WB, and during administration deviation bleeding and the 2 days preceding such bleeding (normalized to a standard 56-day period). Baseline period: 2 days before first menstrual bleeding until 3rd day before 3rd menstrual bleeding (normalized to standard 56-day period). Treatment period: 2 days before WB of the 1st treatment cycle until 3rd day before the WB of the cycle after the 2nd treatment cycle (normalized to standard 56-day period).

Time frame:
baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)
Reported as:
Mean · Days
Change Between Baseline Evaluation Period and Treatment Evaluation Period in Number of Days With Pelvic Pain During Unscheduled Bleeding
DaysEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Change Between Baseline Evaluation Period and Treatment Evaluation Period in Number of Days With Pelvic Pain During Unscheduled Bleeding0.3 ± 2.60.1 ± 2.0
SecondaryChange Between Baseline Evaluation Period and Treatment Evaluation Period in Rescue Medication Use (Only Bleeding Episodes Used Including the Two Days Before the Episode)

Rescue medication use was standardized intake of 200 mg Ibuprofen tablets. Baseline period: 2 days before the first menstrual bleeding until 3rd day before the 3rd menstrual bleeding (normalized to a standard 56-day period). Treatment period: 2 days before the withdrawal bleeding (WB) of the 1st evaluable treatment cycle until 3rd day before the WB of the cycle after the 2nd evaluable treatment cycle (normalized to a standard 56-day period).

Time frame:
baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)
Reported as:
Mean · Tablets
Change Between Baseline Evaluation Period and Treatment Evaluation Period in Rescue Medication Use (Only Bleeding Episodes Used Including the Two Days Before the Episode)
TabletsEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Change Between Baseline Evaluation Period and Treatment Evaluation Period in Rescue Medication Use (Only Bleeding Episodes Used Including the Two Days Before the Episode)-6.2 ± 14.8-6.6 ± 12.3
SecondaryChange Between Baseline Evaluation Period and Treatment Evaluation Period in Rescue Medication Use (Entire Evaluation Period Used)

Rescue medication use was standardized intake of 200 mg Ibuprofen tablets. Baseline period: 2 days before the first menstrual bleeding until 3rd day before the 3rd menstrual bleeding (normalized to a standard 56-day period). Treatment period: 2 days before the withdrawal bleeding (WB) of the 1st evaluable treatment cycle until 3rd day before the WB of the cycle after the 2nd evaluable treatment cycle (normalized to a standard 56-day period).

Time frame:
baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)
Reported as:
Mean · Tablets
Change Between Baseline Evaluation Period and Treatment Evaluation Period in Rescue Medication Use (Entire Evaluation Period Used)
TabletsEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Change Between Baseline Evaluation Period and Treatment Evaluation Period in Rescue Medication Use (Entire Evaluation Period Used)-4.5 ± 19.9-5.6 ± 14.3
SecondaryPercentage of Participants With Interference of Dysmenorrheic Pain With Work/School and Social or Other Activity (Only Bleeding Episodes Used Including the Two Days Before)

Interference of dysmenorrheic pain with work/school and social or other activity was assessed (yes/no). Baseline period: 2 days before the first menstrual bleeding until 3rd day before the 3rd menstrual bleeding (normalized to a standard 56-day period). Treatment period: 2 days before the withdrawal bleeding (WB) of the 1st evaluable treatment cycle until 3rd day before the WB of the cycle after the 2nd evaluable treatment cycle (normalized to a standard 56-day period).

Time frame:
baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)
Reported as:
Number · Percentage of participants
Percentage of Participants With Interference of Dysmenorrheic Pain With Work/School and Social or Other Activity (Only Bleeding Episodes Used Including the Two Days Before)
Percentage of participantsEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Baseline period-daily activities impaired92.391.3
Baseline period- leisure activities impaired90.689.6
Treatment period-daily activities impaired51.756.5
Treatment period- leisure activities impaired47.956.5
SecondaryPercentage of Participants With Interference of Dysmenorrheic Pain With Work/School and Social or Other Activity (Entire Evaluation Period Used)

Interference of dysmenorrheic pain with work/school and social or other activity was assessed (yes/no). Baseline period: 2 days before the first menstrual bleeding until 3rd day before the 3rd menstrual bleeding (normalized to a standard 56-day period). Treatment period: 2 days before the withdrawal bleeding (WB) of the 1st evaluable treatment cycle until 3rd day before the WB of the cycle after the 2nd evaluable treatment cycle (normalized to a standard 56-day period).

Time frame:
baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Interference of Dysmenorrheic Pain With Work/School and Social or Other Activity (Entire Evaluation Period Used)
Percentage of ParticipantsEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Baseline period-daily activities impaired93.292.2
Baseline period- leisure activities impaired92.390.0
Treatment period-daily activities impaired54.760.0
Treatment period- leisure activities impaired52.661.3
SecondaryPercentage of Participants Satisfied With Study Treatment

Participants were asked to express the degree of their satisfaction with study treatment.

Time frame:
From cycle 1 to cycle 3 (28 days per cycle)
Reported as:
Number · Percentage of participants
Percentage of Participants Satisfied With Study Treatment
Percentage of participantsEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Missing0.91.3
Very satisfied53.450.4
Saatisfied32.130.0
Neither satisfied nor dissatisfied7.38.3
Dissatisfied2.13.5
Very dissatisfied0.40.4
SecondaryNumber of Days With Bleeding or Spotting

Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.

Time frame:
From day 1 to day 90
Reported as:
Mean · Days
Number of Days With Bleeding or Spotting
DaysEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Number of Days With Bleeding or Spotting20.0 ± 8.823.6 ± 9.7
SecondaryNumber of Episodes With Bleeding or Spotting

Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.

Time frame:
From day 1 to day 90
Reported as:
Mean · Episodes
Number of Episodes With Bleeding or Spotting
EpisodesEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Number of Episodes With Bleeding or Spotting3.9 ± 1.04.1 ± 0.8
SecondaryMean Length of Bleeding or Spotting Episodes

Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.

Time frame:
From day 1 to day 90
Reported as:
Mean · Days
Mean Length of Bleeding or Spotting Episodes
DaysEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Mean Length of Bleeding or Spotting Episodes5.17 ± 2.265.83 ± 2.35
SecondaryMaximum Length of Bleeding or Spotting Episodes

Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.

Time frame:
From day 1 to day 90
Reported as:
Mean · Days
Maximum Length of Bleeding or Spotting Episodes
DaysEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Maximum Length of Bleeding or Spotting Episodes7.1 ± 3.88.4 ± 5.6
SecondaryDifference in Duration Between Longest and Shortest Bleeding or Spotting Episode

Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.

Time frame:
From day 1 to day 90
Reported as:
Mean · Days
Difference in Duration Between Longest and Shortest Bleeding or Spotting Episode
DaysEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Difference in Duration Between Longest and Shortest Bleeding or Spotting Episode3.6 ± 3.64.6 ± 5.6
SecondaryNumber of Days With Spotting-only

Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.

Time frame:
From day 1 to day 90
Reported as:
Mean · Days
Number of Days With Spotting-only
DaysEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Number of Days With Spotting-only7.3 ± 6.97.6 ± 7.5
SecondaryNumber of Episodes With Spotting-only

Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.

Time frame:
From day 1 to day 90
Reported as:
Mean · Episodes
Number of Episodes With Spotting-only
EpisodesEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Number of Episodes With Spotting-only0.5 ± 0.80.4 ± 0.7
SecondaryMean Length of Spotting Only Episodes

Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.

Time frame:
From day 1 to day 90
Reported as:
Mean · Days
Mean Length of Spotting Only Episodes
DaysEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Mean Length of Spotting Only Episodes3.29 ± 2.393.26 ± 2.79
SecondaryMaximum Length of Spotting Only Episodes

Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.

Time frame:
From day 1 to day 90
Reported as:
Mean · Days
Maximum Length of Spotting Only Episodes
DaysEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Maximum Length of Spotting Only Episodes3.9 ± 3.13.6 ± 3.0
SecondaryDifference in Duration Between Longest and Shortest Spotting Only Episode

Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.

Time frame:
From day 1 to day 90
Reported as:
Mean · Days
Difference in Duration Between Longest and Shortest Spotting Only Episode
DaysEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Difference in Duration Between Longest and Shortest Spotting Only Episode1.2 ± 2.50.7 ± 1.5
SecondaryPercentage of Participants With Withdrawal Bleeding at Cycle 1

Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.

Time frame:
At cycle 1 (28 days per cycle)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Withdrawal Bleeding at Cycle 1
Percentage of ParticipantsEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Percentage of Participants With Withdrawal Bleeding at Cycle 191.293.2
SecondaryPercentage of Participants With Withdrawal Bleeding at Cycle 3

Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.

Time frame:
At cycle 3 (28 days per cycle)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Withdrawal Bleeding at Cycle 3
Percentage of ParticipantsEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Percentage of Participants With Withdrawal Bleeding at Cycle 368.179.3
SecondaryLength of Withdrawal Bleeding Episodes at Cycle 1

Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.

Time frame:
At cycle 1 (28 days per cycle)
Reported as:
Mean · Days
Length of Withdrawal Bleeding Episodes at Cycle 1
DaysEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Length of Withdrawal Bleeding Episodes at Cycle 15.2 ± 2.75.4 ± 2.4
SecondaryLength of Withdrawal Bleeding Episodes at Cycle 3

Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.

Time frame:
At cycle 3 (28 days per cycle)
Reported as:
Mean · Days
Length of Withdrawal Bleeding Episodes at Cycle 3
DaysEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Length of Withdrawal Bleeding Episodes at Cycle 34.5 ± 1.75.2 ± 2.0
SecondaryMaximum Intensity of Withdrawal Bleeding Episodes at Cycle 1

Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. Intensity was defined as: 1 = none, 2 = spotting, 3 = light, 4 = normal, 5 = heavy.

Time frame:
At cycle 1 (28 days per cycle)
Reported as:
Mean · Scores on a scale
Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 1
Scores on a scaleEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 13.7 ± 1.04.0 ± 0.9
SecondaryMaximum Intensity of Withdrawal Bleeding Episodes at Cycle 3

Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. Intensity was defined as: 1 = none, 2 = spotting, 3 = light, 4 = normal, 5 = heavy.

Time frame:
At cycle 3 (28 days per cycle)
Reported as:
Mean · Scores on a scale
Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 3
Scores on a scaleEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 33.7 ± 0.84.1 ± 0.8
SecondaryOnset of Withdrawal Bleeding Episodes at Cycle 1

Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.

Time frame:
At cycle 1 (28 days per cycle)
Reported as:
Mean · Days
Onset of Withdrawal Bleeding Episodes at Cycle 1
DaysEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Onset of Withdrawal Bleeding Episodes at Cycle 14.8 ± 7.04.9 ± 5.9
SecondaryOnset of Withdrawal Bleeding Episodes at Cycle 3

Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.

Time frame:
At cycle 3 (28 days per cycle)
Reported as:
Mean · Days
Onset of Withdrawal Bleeding Episodes at Cycle 3
DaysEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Onset of Withdrawal Bleeding Episodes at Cycle 33.1 ± 3.74.3 ± 4.4
SecondaryPercentage of Participants With Intracyclic Bleeding at Cycle 1

Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.

Time frame:
At cycle 1 (28 days per cycle)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Intracyclic Bleeding at Cycle 1
Percentage of ParticipantsEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Percentage of Participants With Intracyclic Bleeding at Cycle 119.016.7
SecondaryPercentage of Participants With Intracyclic Bleeding at Cycle 3

Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.

Time frame:
At cycle 3 (28 days per cycle)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Intracyclic Bleeding at Cycle 3
Percentage of ParticipantsEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Percentage of Participants With Intracyclic Bleeding at Cycle 310.811.6
SecondaryNumber of Intracyclic Bleeding Episodes at Cycle 1

Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.

Time frame:
At cycle 1 (28 days per cycle)
Reported as:
Mean · Episodes
Number of Intracyclic Bleeding Episodes at Cycle 1
EpisodesEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Number of Intracyclic Bleeding Episodes at Cycle 10.2 ± 0.50.2 ± 0.4
SecondaryNumber of Intracyclic Bleeding Episodes at Cycle 3

Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.

Time frame:
At cycle 3 (28 days per cycle)
Reported as:
Mean · Episodes
Number of Intracyclic Bleeding Episodes at Cycle 3
EpisodesEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Number of Intracyclic Bleeding Episodes at Cycle 30.1 ± 0.30.1 ± 0.4
SecondaryMaximum Length of Intracyclic Bleeding Episodes at Cycle 1

Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.

Time frame:
At cycle 1 (28 days per cycle)
Reported as:
Mean · Days
Maximum Length of Intracyclic Bleeding Episodes at Cycle 1
DaysEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Maximum Length of Intracyclic Bleeding Episodes at Cycle 16.0 ± 5.46.2 ± 5.7
SecondaryMaximum Length of Intracyclic Bleeding Episodes at Cycle 3

Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.

Time frame:
At cycle 3 (28 days per cycle)
Reported as:
Mean · Days
Maximum Length of Intracyclic Bleeding Episodes at Cycle 3
DaysEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Maximum Length of Intracyclic Bleeding Episodes at Cycle 35.5 ± 4.74.9 ± 4.1
SecondaryNumber of Intracyclic Bleeding Days at Cycle 1

Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. The total number of days during intracyclic bleeding episodes was counted.

Time frame:
At cycle 1 (28 days per cycle)
Reported as:
Mean · Days
Number of Intracyclic Bleeding Days at Cycle 1
DaysEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Number of Intracyclic Bleeding Days at Cycle 11.2 ± 3.51.0 ± 3.3
SecondaryNumber of Intracyclic Bleeding Days at Cycle 3

Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. The total number of days during intracyclic bleeding episodes was counted.

Time frame:
At cycle 3 (28 days per cycle)
Reported as:
Mean · Days
Number of Intracyclic Bleeding Days at Cycle 3
DaysEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Number of Intracyclic Bleeding Days at Cycle 30.6 ± 2.30.6 ± 2.1
SecondaryPercentage of Participants With Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 1

Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. Intensity could be described as spotting, light, normal or heavy.

Time frame:
At cycle 1 (28 days per cycle)
Reported as:
Number · Percentage of participants
Percentage of Participants With Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 1
Percentage of participantsEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Spotting53.562.2
Light30.210.8
Normal9.313.5
Heavy7.013.5
SecondaryPercentage of Participants With Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 3

Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. Intensity could be described as spotting, light, normal or heavy.

Time frame:
At cycle 3 (28 days per cycle)
Reported as:
Number · Percentage of participants
Percentage of Participants With Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 3
Percentage of participantsEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Spotting45.530.4
Light27.321.7
Normal13.630.4
Heavy13.617.4
SecondaryPercentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Screening

The investigator was asked to interview the participant and record the number of missed hours/days from work due to dysmenorrheic pain in the previous menstrual cycle.

Time frame:
At screening (28 days)
Reported as:
Number · Percentage of Participants
Percentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Screening
Percentage of ParticipantsEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Missing0.40.0
Never38.040.4
4 working hours16.216.1
1 working day26.529.6
>= 2 working days18.813.9
SecondaryPercentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Baseline Cycle

The investigator was asked to interview the participant and record the number of missed hours/days from work due to dysmenorrheic pain in the previous menstrual cycle.

Time frame:
At Baseline (28 days per cycle)
Reported as:
Number · Percentage of Participants
Percentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Baseline Cycle
Percentage of ParticipantsEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Missing0.00.0
Never47.951.7
4 working hours13.211.7
1 working day20.923.9
>= 2 working days17.912.2
SecondaryPercentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Cycle 2

The investigator was asked to interview the participant and record the number of missed hours/days from work due to dysmenorrheic pain in the previous menstrual cycle.

Time frame:
At cycle 2 (28 days per cycle)
Reported as:
Number · Percentage of Participants
Percentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Cycle 2
Percentage of ParticipantsEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Missing0.00.0
Never78.672.6
4 working hours8.56.5
1 working day6.48.7
>= 2 working days2.14.3
SecondaryPercentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Final Examination

The investigator was asked to interview the participant and record the number of missed hours/days from work due to dysmenorrheic pain in the previous menstrual cycle.

Time frame:
At final examination (28 days)
Reported as:
Number · Percentage of Participants
Percentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Final Examination
Percentage of ParticipantsEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Missing0.40.0
Never85.985.2
4 working hours5.62.6
1 working day3.04.8
>= 2 working days1.71.7
SecondaryOwn Costs of Physiotherapy Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire

The participants were asked to complete a resource use questionnaire indicating their own costs of physiotherapy per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars.

Time frame:
At screening (average over 3 months before screening)
Reported as:
Median · Dollars
Own Costs of Physiotherapy Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
DollarsEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Own Costs of Physiotherapy Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
SecondaryOwn Costs of Pain Medication Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire

The participants were asked to complete a resource use questionnaire indicating their own costs of pain medication per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars.

Time frame:
At screening (average over 3 months before screening)
Reported as:
Median · Dollars
Own Costs of Pain Medication Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
DollarsEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Own Costs of Pain Medication Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire5.46 (0.00 to 30.00)5.04 (0.00 to 27.49)
SecondaryOwn Costs of Vitamins Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire

The participants were asked to complete a resource use questionnaire indicating their own costs of vitamins per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars.

Time frame:
At screening (average over 3 months before screening)
Reported as:
Median · Dollars
Own Costs of Vitamins Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
DollarsEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Own Costs of Vitamins Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire0.00 (0.00 to 65.45)0.00 (0.00 to 65.45)
SecondaryOwn Costs of Massages Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire

The participants were asked to complete a resource use questionnaire indicating their own costs of massages per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars.

Time frame:
At screening (average over 3 months before screening)
Reported as:
Median · Dollars
Own Costs of Massages Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
DollarsEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Own Costs of Massages Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire0.00 (0.00 to 60.00)0.00 (0.00 to 295.98)
SecondaryOwn Costs of Acupuncture Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire

The participants were asked to complete a resource use questionnaire indicating their own costs of acupuncture per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars.

Time frame:
At screening (average over 3 months before screening)
Reported as:
Median · Dollars
Own Costs of Acupuncture Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
DollarsEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Own Costs of Acupuncture Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire0.00 (0.00 to 150.00)0.00 (0.00 to 74.00)
SecondaryOwn Costs of Medical Counseling Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire

The participants were asked to complete a resource use questionnaire indicating their own costs of medical counseling per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars.

Time frame:
At screening (average over 3 months before screening)
Reported as:
Median · Dollars
Own Costs of Medical Counseling Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
DollarsEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Own Costs of Medical Counseling Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire0.00 (0.00 to 271.68)0.00 (0.00 to 98.17)
SecondaryOwn Costs of Alternative Medicine Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire

The participants were asked to complete a resource use questionnaire indicating their own costs of alternative medicine per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars.

Time frame:
At screening (average over 3 months before screening)
Reported as:
Median · Dollars
Own Costs of Alternative Medicine Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
DollarsEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Own Costs of Alternative Medicine Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire0.00 (0.00 to 196.34)0.00 (0.00 to 110.00)
SecondaryOwn Costs of Herbs/Teas Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire

The participants were asked to complete a resource use questionnaire indicating their own costs of herbs/teas per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars.

Time frame:
At screening (average over 3 months before screening)
Reported as:
Median · Dollars
Own Costs of Herbs/Teas Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
DollarsEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Own Costs of Herbs/Teas Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire0.00 (0.00 to 30.00)0.00 (0.00 to 10.00)
SecondaryOther Own Costs Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire

The participants were asked to complete a resource use questionnaire indicating their other own costs per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars.

Time frame:
At screening (average over 3 months before screening)
Reported as:
Median · Dollars
Other Own Costs Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
DollarsEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Other Own Costs Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire0.00 (0.00 to 15.00)0.00 (0.00 to 42.00)
SecondaryParticipants With Improvement in the Investigators' Assessment in the Clinical Global Impression

The Clinical Global Impression Scale (CGI) is a widely used rating scale/assessment instrument in psychopharmacology research in general, and in studies on women's health in particular. Investigators were asked to rate the participants' improvement during the course of the study.

Time frame:
At cycle 2 (28 days per cycle)
Reported as:
Number · Participants
Participants With Improvement in the Investigators' Assessment in the Clinical Global Impression
ParticipantsEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Missing00
Not assessed11
Very much improved6342
Much improved8784
Minimally improved4954
No change1723
Minimally worse63
Much worse06
SecondaryParticipants With Improvement in Participants' Assessment in the Clinical Global Impression

The Clinical Global Impression Scale (CGI) is a widely used rating scale/assessment instrument in psychopharmacology research in general, and in studies on women's health in particular. Participants were asked to rate their improvement during the course of the study.

Time frame:
At cycle 2 (28 days per cycle)
Reported as:
Number · Participants
Participants With Improvement in Participants' Assessment in the Clinical Global Impression
ParticipantsEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Missing10
Not assessed11
Very much improved6046
Much improved9175
Minimally improved4757
No change1824
Minimally worse54
Much worse03
SecondaryPhysical Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)

Time frame:
At baseline cycle (28 days per cycle)
Reported as:
Mean · Scores on a scale
Physical Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
Scores on a scaleEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Physical Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle90.2 ± 16.789.6 ± 17.5
SecondaryPhysical Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)

Time frame:
at final examination (28 days)
Reported as:
Mean · Scores on a scale
Physical Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
Scores on a scaleEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Physical Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination93.7 ± 14.292.5 ± 15.0
SecondarySocial Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)

Time frame:
At baseline cycle (28 days per cycle)
Reported as:
Mean · Scores on a scale
Social Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
Scores on a scaleEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Social Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle78.85 ± 18.9977.35 ± 20.56
SecondarySocial Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)

Time frame:
At final examination (28 days)
Reported as:
Mean · Scores on a scale
Social Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
Scores on a scaleEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Social Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination85.95 ± 19.0984.79 ± 17.36
SecondaryMental Health as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)

Time frame:
At baseline cycle (28 days per cycle)
Reported as:
Mean · Scores on a scale
Mental Health as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
Scores on a scaleEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Mental Health as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle73.6 ± 15.672.6 ± 16.3
SecondaryMental Health as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)

Time frame:
At final examination (28 days)
Reported as:
Mean · Scores on a scale
Mental Health as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
Scores on a scaleEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Mental Health as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination77.3 ± 14.976.4 ± 14.7
SecondaryVitality as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)

Time frame:
At baseline cycle (28 days per cycle)
Reported as:
Mean · Scores on a scale
Vitality as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
Scores on a scaleEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Vitality as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle62.6 ± 18.062.2 ± 18.2
SecondaryVitality as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)

Time frame:
At final examination (28 days)
Reported as:
Mean · Scores on a scale
Vitality as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
Scores on a scaleEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Vitality as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination68.2 ± 17.067.2 ± 16.8
SecondaryGeneral Health as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)

Time frame:
At baseline cycle (28 days per cycle)
Reported as:
Mean · Scores on a scale
General Health as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
Scores on a scaleEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
General Health as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle75.8 ± 17.572.7 ± 16.9
SecondaryGeneral Health as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)

Time frame:
At final examination (28 days)
Reported as:
Mean · Scores on a scale
General Health as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
Scores on a scaleEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
General Health as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination77.2 ± 17.976.5 ± 16.6
SecondaryRole Physical as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)

Time frame:
At baseline cycle (28 days per cycle)
Reported as:
Mean · Scores on a scale
Role Physical as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
Scores on a scaleEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Role Physical as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle77.8 ± 33.679.4 ± 32.7
SecondaryRole Physical as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)

Time frame:
At final examination (28 days)
Reported as:
Mean · Scores on a scale
Role Physical as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
Scores on a scaleEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Role Physical as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination89.6 ± 23.087.9 ± 25.9
SecondaryRole Emotional as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)

Time frame:
At baseline cycle (28 days per cycle)
Reported as:
Mean · Scores on a scale
Role Emotional as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
Scores on a scaleEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Role Emotional as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle81.91 ± 31.5079.18 ± 34.74
SecondaryRole Emotional as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)

Time frame:
At final examination (28 days)
Reported as:
Mean · Scores on a scale
Role Emotional as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
Scores on a scaleEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Role Emotional as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination88.64 ± 26.3683.87 ± 30.28
SecondaryBodily Pain as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)

Time frame:
At baseline cycle (28 days per cycle)
Reported as:
Mean · Scores on a scale
Bodily Pain as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
Scores on a scaleEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Bodily Pain as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle50.7 ± 24.451.8 ± 23.0
SecondaryBodily Pain as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination

The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)

Time frame:
At final examination (28 days)
Reported as:
Mean · Scores on a scale
Bodily Pain as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
Scores on a scaleEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Bodily Pain as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination77.0 ± 21.574.0 ± 22.1

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)—2/234 (0.9%)131/234 (56%)
Ethinyl Estradiol, Levonorgestrel (Miranova)—2/230 (0.9%)122/230 (53%)
Most frequent serious events
Most frequent serious events
EventEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
Animal biteInjury, poisoning and procedural complications0/2341/230
DepressionPsychiatric disorders0/2341/230
Helminthic infectionInfections and infestations1/2340/230
Ovarian torsionReproductive system and breast disorders1/2340/230
Most frequent other events
Showing 10 of 12
Most frequent other events
EventEstradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)
DysmenorrhoeaReproductive system and breast disorders87/23482/230
HeadacheNervous system disorders32/23434/230
MetrorrhagiaReproductive system and breast disorders18/23413/230
Tension headacheNervous system disorders14/2349/230
Cervical dysplasiaReproductive system and breast disorders7/2349/230
Cervix inflammationReproductive system and breast disorders9/2344/230
Upper respiratory tract infectionInfections and infestations4/2347/230
InflammationGeneral disorders7/2343/230
NauseaGastrointestinal disorders2/2345/230
InfluenzaInfections and infestations2/2345/230

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)Total
Mean28.0 ± 7.927.6 ± 8.027.8 ± 7.9
Age, Customized
Age, Customized(Participants)Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)Total
less than 18 years of age111324
18 years of age or older223217440
Sex: Female, Male
Sex: Female, Male(Participants)Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Ethinyl Estradiol, Levonorgestrel (Miranova)Total
Female234230464
Male000
08

Study locations

42 sites
  • Tucson, Arizona 85741, United States
  • San Diego, California 92108, United States
  • Hialeah, Florida 33012, United States
  • Leesburg, Florida 34748, United States
  • Sandy Springs, Georgia 30328, United States
  • Idaho Falls, Idaho 83404, United States
  • Winston-Salem, North Carolina 27103, United States
  • Philadelphia, Pennsylvania 19114, United States
  • Pittsburgh, Pennsylvania 15206, United States
  • La Crosse, Wisconsin 54691, United States
  • Langley, British Columbia V3A 4H9, Canada
  • Toronto, Ontario M5C 2T2, Canada
  • Pointe-Claire, Quebec H9R 4S3, Canada
  • Ste-Foy, Quebec G1V 4X7, Canada
  • Regina, Saskatchewan S4P 3X1, Canada
  • Santiago de Chile, Chile
  • Santiago, Chile
  • Talcahuano, Chile
  • Temuco, 4790711, Chile
  • Freiburg, Baden-Württemberg 79106, Germany
  • Essen, Nordrhein-Westfalen 45127, Germany
  • Köln, Nordrhein-Westfalen 50931, Germany
  • Bernburg, Sachsen-Anhalt 06406, Germany
  • Magdeburg, Sachsen-Anhalt 39126, Germany
  • Leipzig, Sachsen 04207, Germany
  • Hamburg, 22159, Germany
  • Francavilla Fontana, Brindisi 72021, Italy
  • Bologna, 40138, Italy
  • Brescia, 25123, Italy
  • Milano, 20121, Italy
  • Modena, 41124, Italy
  • Perugia, 06156, Italy
  • Roma, 00161, Italy
  • Siena, 53100, Italy
  • Torino, 10126, Italy
  • Udine, 33100, Italy
  • Cebu City, Philippines
  • Cebu, Philippines
  • Davao, Philippines
  • Metro Manila, 1000, Philippines
  • Metro Manila, Philippines
  • Quezon City, Philippines
09

References and documents

Publications

  • Petraglia F, Parke S, Serrani M, Mellinger U, Romer T. Estradiol valerate plus dienogest versus ethinylestradiol plus levonorgestrel for the treatment of primary dysmenorrhea. Int J Gynaecol Obstet. 2014 Jun;125(3):270-4. doi: 10.1016/j.ijgo.2013.11.017. Epub 2014 Mar 11. PubMed 24713413 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2012, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2009
First posted
May 29, 2009
Start
Apr 2009
Primary completionActual
Nov 2010
CompletionActual
Nov 2010
Results first posted
Feb 27, 2012
Last update
Aug 24, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00909857
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
May 29, 2009
Start date
Apr 2009
Primary completion
Nov 2010
Completion
Nov 2010
Results posted
Feb 27, 2012
Last update
Aug 24, 2015

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Estradiol · Dienogest

Start the discussion